Is the development of a new tuberculosis vaccine possible?

Whereas federal expenditure in the United States on the development of an HIV/AIDS vaccine is approximately $250 million, only $25 million is spent on research and development for a malaria vaccine. It is not malaria but tuberculosis (TB) that is the poor relation. Government funds for a vaccine to fight this disease are in single figure millions. Stefan Kaufmann of the Max Planck Institute for Infection Biology examines obstacles in addition to funding that hinder the development of a new TB vaccine.

[1]  M. Horwitz,et al.  The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease , 1996, Nature Medicine.

[2]  P D van Helden,et al.  Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. , 1999, The New England journal of medicine.

[3]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[4]  A. Alcamí,et al.  Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. , 1998, The Journal of general virology.

[5]  K. Moelling,et al.  Therapy of tuberculosis in mice by DNA vaccination , 1999, Nature.

[6]  J. Sprent,et al.  Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo , 1996, Science.

[7]  Donna L. Montgomery,et al.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.

[8]  P. E. M. Fine,et al.  Variation in protection by BCG: implications of and for heterologous immunity , 1995, The Lancet.

[9]  J. Venter,et al.  From genomics to vaccines: Malaria as a model system , 1998, Nature Medicine.

[10]  M. Colston,et al.  Vaccination against tuberculosis by DNA injection , 1996, Nature Medicine.

[11]  P. Gounon,et al.  Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. , 1998, Science.

[12]  S. Hoffman,et al.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Hill,et al.  The immunogenetics of human infectious diseases. , 1998, Annual review of immunology.

[14]  S. Kaufmann,et al.  Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Global Tuberculosis Programme.  Global tuberculosis control : WHO report , 1997 .

[16]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. , 1993, International immunology.

[17]  S. H. Kaufmann,et al.  Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens , 1999, Molecular microbiology.

[18]  D. Sherratt,et al.  Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. , 1998, Nucleic acids research.

[19]  J. Frelinger,et al.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians , 1997, Journal of virology.

[20]  Octavio Gómez Dantés,et al.  The World Health Report 1999. Making a Difference , 1999 .

[21]  S. Kaufmann,et al.  Exploiting the immune system: toward new vaccines against intracellular bacteria. , 2000, Advances in immunology.

[22]  M. Behr.  Comparative genomics of BCG vaccines. , 2001, Tuberculosis.